1023 / 1835
•
CMT has been the standard (with CHOP)
•
Recent changes:
–
Rituximab
improved PFS & OS
–
PET
response assessment
–
Omitting RT in HL
•
Need to revaluate role of RT in DLBCL
|
|
1023 / 1835
•
CMT has been the standard (with CHOP)
•
Recent changes:
–
Rituximab
improved PFS & OS
–
PET
response assessment
–
Omitting RT in HL
•
Need to revaluate role of RT in DLBCL